Document is current
Any future updates will be listed below
-
Authors
Coffey, Lark L. https://orcid.org/0000-0002-0718-5146
Olstad, Katherine J. https://orcid.org/0000-0003-3894-0981
Reader, J. Rachel
Ardeshir, Amir
Weiss, Christopher M. https://orcid.org/0000-0003-4704-9533
Watanabe, Jennifer K.
Usachenko, Jodie L.
Yee, JoAnn
Singapuri, Anil
Ma, Zhong Min
Mackiewicz, Alexis
Sammak, Rebecca
Stuart, Jackson
Immareddy, Ramya
Anantha, Ravi
Warfield, Kelly L. https://orcid.org/0000-0003-1866-5388
Manayani, Darly
Alexander, Jeff
Smith, Jonathan
Vang, Lo
Cirimotich, Christopher M. https://orcid.org/0000-0002-7636-0542
O’Connor, Cassandra
Guenther, Ben
Ho, Nhuxuan
Morello, Christopher S.
Mendy, Jason
Richardson, Jason S.
Van Rompay, Koen K. A. https://orcid.org/0000-0002-7375-1337
-
Funding
Funding for this research was provided by:
PaxVax
Office of Research Infrastructure Programs (P51 OD011107)
- License Information
-
More Information
Article History
Received: 5 November 2025
Accepted: 24 February 2026
First Online: 18 March 2026
Competing interests
: The funders of the study had a role in study design, data collection, data analysis, data interpretation, and writing of the manuscript. J.S.R., B.G., and N.H. are employees of Bavarian Nordic. J.S.R. own stock or stock options in Bavarian Nordic. C.S.M. and K.L.W. own stock in Emergent Biosolutions. Other authors declare no competing interests.
